Europe is facing a new squeeze in the pharmaceutical sector. On one side, the United States is turning drug pricing and supply chains into harder bargaining tools, raising uncertainty for global launch strategies and investment plans. On the other hand, China is rapidly expanding its role in biotech innovation, increasingly positioning itself as a source of new drug candidates and a partner for global licensing and development. The combined effect is a gradual shift in where research, capital, and high-value projects are being placed.
For decades, Europe was viewed as a natural home for major drugmakers and a leading center of research. That dominance has faded. Long-run estimates show Europe's share of global research and development has fallen sharply over time, while the United States has gained ground and now holds the largest share. This is not simply a cyclical change. It reflects structural advantages elsewhere and persistent frictions within Europe that make large-scale innovation harder to fund and slower to commercialize.
Launch decisions are becoming more complicated
The most immediate pressure point is the interaction between pricing and launch timing. If U.S. policy moves toward tying domestic drug prices to the lowest prices paid in comparable markets, drugmakers face a difficult choice: launch quickly in lower-price jurisdictions and risk pulling U.S. prices down, or delay launches in Europe to protect U.S. profitability. That can slow access for European patients and weaken the commercial case for prioritizing Europe as an early launch market.
Even without sweeping policy changes, the United States remains the most profitable market for many therapies, which naturally pulls investment toward American manufacturing, clinical development, and commercialization. New tariff threats and a sharper national-security framing around biotech supply chains add to that gravitational pull by making domestic production more attractive and potentially more politically protected.
China is no longer only a market, it is an innovation source
At the same time, China's biotech ecosystem has matured quickly. Estimates show that a growing share of the global drug development pipeline now originates from Chinese-developed molecules, rising from a small fraction a decade ago to a meaningful portion today. This matters because the innovation engine of pharma is the pipeline. If more early-stage science and licensing opportunities are emerging in China, capital and partnership activity tend to follow.
Research on cross-border R&D flows has also pointed to China as a major net recipient of foreign R&D, while Europe has been less successful than the United States at attracting and retaining research activity. That aligns with what companies often say privately: innovation follows ecosystems where science, capital, talent, and speed of execution are tightly connected.
Europe's internal barriers remain the core issue
Europe's challenge is not a lack of scientific talent. The issue is translation. Funding is more fragmented, regulation is more complex across multiple jurisdictions, and reimbursement pathways are uneven, which makes it harder to build scale and predict returns. Compared with the United States, Europe's biotech sector has historically received far less venture capital, limiting startups' ability to move quickly from discovery to clinical trials and commercialization.
Spending levels also matter. Industry groups argue that Europe spends a smaller share of GDP on pharmaceuticals than the United States, and that long periods of flat medicine spending have reduced incentives to prioritize fast launches and larger R&D footprints. They also point to clawbacks, rebates, and taxes as factors that erode returns and slow reinvestment.
Why this matters beyond the sector
Pharmaceuticals have been a meaningful contributor to Europe's trade balance. The industry's strength supports high-skilled employment, manufacturing, and a broad supplier base. If investment drifts elsewhere, Europe risks not only slower access to new medicines but also a gradual weakening of a strategically important export and innovation pillar.
Signs of response, but execution is the test
European policymakers have begun to respond with proposals to streamline biotech rules, accelerate clinical trials, and improve the investment environment. There are also efforts focused on securing the supply of critical medicines, following shortages that exposed vulnerabilities during the pandemic. Some countries have shown that targeted support can improve competitiveness in niches like clinical research.
Still, the central question is speed and consistency. Improving price signals alone is unlikely to be sufficient if regulatory complexity, funding gaps, and market fragmentation persist. Europe can stabilize its position, but doing so requires coordinated reforms that make it easier to fund innovation, run trials, and launch medicines across the region without excessive delay or uncertainty.
Bottom line
Two forces are pressuring Europe at once: tougher U.S. policy leverage on pricing and supply chains, and China's rapid ascent as a biotech innovator. The near-term risk is delayed European launches and a slow reallocation of R&D and capital away from Europe. The longer-term risk is structural: if Europe cannot reduce fragmentation and improve the economics of innovation, it may remain a secondary priority for the next generation of high-impact medicines.